Drawing for CLEAR CROSSING

USPTO serial 99557550

CLEAR CROSSING

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
STEINPFAD, SARAH E
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).

Status 686: Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance.

Need help with CLEAR CROSSING?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sheila Fox Morrison

Sheila Fox Morrison Davis Wright Tremaine LLP560 SW 10th Avenue, Suite 700Portland, OR 97205United States

Goods and services

ClassDescriptionStatusFirst use
005drug delivery agents consisting of compounds that facilitate delivery of wide range of pharmaceuticals; drug delivery agents in the form of powders and liquids that facilitate the delivery of a wide range of pharmaceuticals; drug delivery agents consisting of compounds that improve the efficacy of other drug delivery agents, all to facilitate the delivery of a wide range of pharmaceuticals; Pharmaceutical preparations in the nature of drug delivery agents consisting of compounds for intracellular delivery of drugs or therapeutic substances; drug delivery agents consisting of compounds for intracellular delivery of biological or chemical compounds for biological researchACTIVE—
040biomanufacturing services of peptides for others in the nature of peptide synthesis for biological and medical research; biomanufacturing services of peptides for others in the nature of peptide synthesis for manufacturers of biological and medical research productsACTIVE—
042pharmaceutical research and development; biochemical research and development; research and development in the field of drug delivery and drug delivery systems; chemical analysis of biological and chemical compounds; chemical analysis services; scientific and technological services, namely, product design and development in the field of peptide synthesis for biological and medical research; scientific and technological services, namely, laboratory services for biomanufacturing peptides in the nature of peptide synthesis for manufacturers of biological and medical research products; scientific and technological services, namely, biological and medical research in the field of peptide synthesisACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 28, 2026ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Oct 20, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Oct 20, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 14, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Sep 22, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 18, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 18, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 18, 2026ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jul 6, 2026GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jul 6, 2026GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 6, 2026CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 1, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 1, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 1, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 30, 2026GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 30, 2026GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 30, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 22, 2026DOCKASSIGNED TO EXAMINER—
Dec 19, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Dec 19, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 19, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance